



Trileptal[®] (oxcarbazepine) – New contraindication and warning

- On March 23, 2017, the [FDA approved](#) new updates to the [Trileptal \(oxcarbazepine\)](#) drug label.
- Trileptal is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults, and as monotherapy in the treatment of partial seizures in pediatric patients aged 4 years and above with epilepsy, and as adjunctive therapy in pediatric patients aged 2 years and above with partial seizures.
- A new update was added to the *Contraindications* section stating that Trileptal is contraindicated in patients with a known hypersensitivity to [Aptiom[®] \(eslicarbazepine\)](#).
- The *Warnings and Precautions* section was updated with new information regarding risk of seizure aggravation.
- Exacerbation of or new onset primary generalized seizures has been reported with Trileptal. The risk of aggravation of primary generalized seizures is seen especially in children but may also occur in adults. In case of seizure aggravation, Trileptal should be discontinued.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.